A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (5.0 mg or 2.5 mg) of MIN-117 in Adult Patients With Major Depressive Disorder
Latest Information Update: 22 Dec 2021
At a glance
- Drugs MIN 117 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Minerva Neurosciences
- 17 Jan 2020 Status changed from active, no longer recruiting to completed.
- 23 Dec 2019 This trial has been completed in Finland, according to European Clinical Trials Database. (2019-11-21)
- 04 Nov 2019 Status changed from recruiting to active, no longer recruiting, according to a Minerva Neurosciences media release.